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Abstract
Background: The mechanisms that consolidate neural circuitry are a major focus of neuroscience. In the
mammalian cochlea, the refinement of spiral ganglion neuron (SGN) innervation to the inner hair cells (by type I
SGNs) and the outer hair cells (by type II SGNs) is accompanied by a 25% loss of SGNs.
Results: We investigated the segregation of neuronal loss in the mouse cochlea using b-tubulin and peripherin
antisera to immunolabel all SGNs and selectively type II SGNs, respectively, and discovered that it is the type II SGN
population that is predominately lost within the first postnatal week. Developmental neuronal loss has been
attributed to the decline in neurotrophin expression by the target hair cells during this period, so we next
examined survival of SGN sub-populations using tissue culture of the mid apex-mid turn region of neonatal mouse
cochleae. In organotypic culture for 48 hours from postnatal day 1, endogenous trophic support from the organ of
Corti proved sufficient to maintain all type II SGNs; however, a large proportion of type I SGNs were lost. Culture of
the spiral ganglion as an explant, with removal of the organ of Corti, led to loss of the majority of both SGN sub-
types. Brain-derived neurotrophic factor (BDNF) added as a supplement to the media rescued a significant
proportion of the SGNs, particularly the type II SGNs, which also showed increased neuritogenesis. The known
decline in BDNF production by the rodent sensory epithelium after birth is therefore a likely mediator of type II
neuron apoptosis.
Conclusion: Our study thus indicates that BDNF supply from the organ of Corti supports consolidation of type II
innervation in the neonatal mouse cochlea. In contrast, type I SGNs likely rely on additional sources for trophic
support.
Background
Development of the nervous system is characterized by
the pruning of inappropriate contacts through synapse
elimination [1], axon retraction [2] and by apoptosis of
neurons [3,4]. In the cochlea, these processes refine
afferent innervation of the sensory hair cells during
early development, resulting in the precise pattern of
innervation observed in the adult.
The mature mammalian cochlea exhibits segregated
innervation of its two populations of sensory hair cells
by the spiral ganglion neurons (SGNs), the primary
auditory neurons. Type I SGNs comprise 90 to 95% of
the SGN population and 10 to 20 of these neurons
extend single, unbranched, myelinated neurites to exclu-
sively innervate a single inner hair cell (IHC). The IHCs
with their highly convergent and exclusively type I SGN
innervation are responsible for encoding sound stimuli.
The remaining 5 to 10% of SGNs are type II neurons
that extend thin, unmyelinat e df i b e r st h a ti n n e r v a t e
numerous outer hair cells (OHCs) in an en passant
fashion. Auditory coding from the type II SGNs has not
been determined but it is thought to signal the operat-
ing point of the ‘cochlear amplifier’ or active enhance-
m e n to fs o u n dt r a n s d u c t i o nt h a ti sa s s o c i a t e dw i t ht h e
OHC [5,6]. This highly conserved afferent innervation of
IHCs and OHCs is established during the first postnatal
week of development in rodents. Type I arbors, which
initially project to both hair cell types, withdraw from
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single IHC [7-11]. Type II fibers lose any contact to the
IHC region, turn basally, a process that requires expres-
sion of the transcription factor Prox1 [12], and increase
their length five-fold as they extend within the outer
spiral bundles beneath the rows of OHCs [7]. This post-
natal period is also known to be characterized by apop-
tosis of approximately 25% of SGNs [13,14].
Studies in the visual system of chicks show that pro-
grammed cell death provides a means of removing neur-
ites that have innervated inappropriate targets [15] and
is thought to arise from restriction of neurotrophin sup-
ply from target tissue [3]. In the developing inner ear,
brain-derived neurotrophic factor (BDNF) and neurotro-
phin-3 (NT-3) are necessary for the survival of SGNs
[16-18]. Both BDNF and NT-3 are expressed by the sen-
sory hair cells in the developing organ of Corti. In the
mouse, NT-3 is broadly expressed in the organ of Corti
at birth (with an apically biased gradient), becoming
constrained to the inner hair cells and adjacent support-
ing cells after the onset of hearing (second postnatal
week) [19]. At birth, BDNF expression is largely con-
strained to the IHCs and OHCs [20] and is then down-
regulated from the basal turn upwards, reflecting pro-
gressive maturation of the developing organ of Corti
[21,22]. Null mutants for BDNF and NT-3, or their
respective TrkB and TrkC receptors, cause a loss of
SGNs during embryogenesis [23-25]; disruption of
BDNF/TrkB signaling particularly affects type II SGNs
and their innervation of OHCs. Knock-in of BDNF
expression under the NT-3 promoter [26] and, conver-
sely, knock-in of NT-3 under the BDNF promoter [27]
indicated that BDNF, or NT-3 substituting for the
BDNF spatiotemporal expression profile in the neonatal
cochlea, supports both type I and type II SGN survival
and the development of the type II SGN innervation of
the OHC.
Our study sought to clarify the molecular signaling
that determines how the two different populations of
primary afferent neurons segregate in the developing
cochlea to innervate their respective targets, the IHCs
and the OHCs. We utilized the mouse model, which
benefits from the selective expression by type II SGNs
of peripherin, a type III intermediate filament [8]. By
immunolabeling peripherin-positive type II SGNs and
comparing this with immunolabeling of both popula-
tions of SGNs with an anti-b-tubulin antibody, we were
able to determine the fate of the two SGN neuron popu-
lations in vivo and in vitro during the critical final reso-
lution of afferent innervation of the cochlea in the first
postnatal week, just prior to the onset of hearing. Our
findings reveal a differential dependency on BDNF neu-
rotrophic support for survival and neuritogenesis of the
type II versus type I spiral ganglion afferent neurons.
Results
In this study we investigated the density of type I and
type II SGNs in vivo and in vitro to gain further insight
into the mechanisms that maintain these neuronal sub-
types during postnatal development. b-Tubulin anti-
serum allowed identification of the total SGN popula-
tion [28-34] and double immunolabeling for peripherin
distinguished the type II SGNs and their neurites [8] in
cochlear tissue from postnatal day (P)1 and P7 mice
compared with P21 as a mature reference. This period
encompassed the refinement of afferent innervation in
the mouse cochlea (Figure 1) [8].
In vivo spiral ganglion neuron density
At P1 the spiral ganglion contained many type II SGNs,
identified as b-tubulin and peripherin double-immunola-
beled (Figures 1A,B and 2A-C). The type II SGNs had
somata distributed throughout the ganglion and neurites
predominantly projecting to OHCs, with minor side
projections to IHCs (Figure 1C,D). The type I SGN
somata were the majority, and their fibers (immunola-
beled for b-tubulin but not peripherin) formed a dense
inner spiral plexus (ISP) at the base of the IHCs. In con-
trast, cochleae from P7 mice exhibited a reduced num-
ber of peripherin immunolabeled type II SGNs (Figure
2E,F). These type II SGNs were localized near the intra-
ganglionic spiral bundle and b-tubulin expression in
their soma appeared reduced in P7 (Figures 1E,F and
2E,F) and P21 (Figure 2H,I) cochleae and reflects pre-
v i o u sf i n d i n g sb yL a l l e m e n da n dc o l l e a g u e s[ 3 1 ] ,w h o
showed a downregulation of this protein in rat type II
SGNs from P5. Type II fibers innervated only the OHCs
(Figure 1E-H), matching the adult-like distribution at
P21 (Figure 2G-I). There was no evidence of the type II
fiber innervation of the IHCs that was observed at P1
(arrow in Figure 1C,D). Type I SGN innervation was
consolidated at the ISP, associated with the basolateral
region of the IHC (Figure 1E-G).
To further investigate the apparent loss of peripherin
immunolabeled type II SGNs during postnatal develop-
ment, we examined the density of type I and type II
SGNs in spiral ganglia from cryosectioned P1 (n = 4),
P7 (n = 5) and P21 (n = 5) mouse cochleae (Figures 2
and 3). The most apical region of the spiral ganglia
lacked peripherin-positive type II SGNs in P1 (Figures
2A and 3C), P7 (Figures 2D and 3C) and P21 (Figures
2G and 3C) mice.
b-Tubulin expression permitted quantification of
neuron density for the total SGN population (Figures 2
and 3A), which showed an approximately 25% reduc-
tion in density between P1 and P21 (P1 = 497 ± 51
neurons/100 μm
3; P7 = 327 ± 11 neurons/100 μm
3;
P21 = 363 ± 28 neurons/100 μm
3;o n e - w a yA N O V A ,P
< 0.01). This significant loss of SGNs occurred
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0.05). Type I SGNs, which expressed b-tubulin only
(Figure 2), showed neuron densities of 376 ± 92 neu-
rons/100 μm
3, 312 ± 27 neurons/100 μm
3 and 352 ±
28 neurons/100 μm
3 for P1, P7 and P21 cochleae,
respectively (Figure 3A), and were not significantly dif-
ferent (one-way ANOVA, P = 0.268). Peripherin and
b-tubulin immuno-positive type II SGNs (Figure 2),
however, showed a marked and significant reduction in
neuron density between P1 and P21 (Figure 3A; one-
Figure 1 Double labeling for b-tubulin and peripherin distinguishes type I and type II spiral ganglion neurons (SGNs) and their
peripheral innervation during the first postnatal week of mouse development. Single plane (A,C,D,E,G,H) and maximum projections (B,F) of
confocal image stacks show b-tubulin (green) and peripherin (red) immunofluorescence in cochleae from P1 (A-D) and P7 (E-H) mice. (A-D) At
P1 peripheral fibers from type I SGNs (immunolabeled for b-tubulin only) form the inner spiral plexus (isp) beneath the inner hair cell (ihc). Type
II SGN soma and peripheral fibers (b-tubulin and peripherin immunolabeled) are numerous in the spiral ganglion (sgn) and osseus spiral lamina
(osl) of P1 cochleae (A,B). Their neurites are present beneath the IHCs (arrow in (C,D)) and beneath the outer hair cells (ohc) in the outer spiral
bundles (osb). (E-H) At P7, the majority of neurons in the spiral ganglion are type I neurons (E,F) and their neurites innervate the IHCs (G).
Peripherin and b-tubulin double-immunolabeled type II SGNs are now localized laterally in the spiral ganglion near the intra-ganglionic spiral
bundle (igsb), their fibers form the outer spiral bundle and innervate the OHC only; no peripherin-immunolabeled fibers extend toward the IHC
(H). Variation in the color (yellow to red) of double labeled (type II) neuron soma and their neurite processes arises from differences in the
relative intensity of the b-tubulin (green fluorescence) in soma and neurites and also peripherin (red) fluorescence in merged confocal images.
This is particularly evident at P7, where the type II soma appear red as there is a decline in b-tubulin labeling, whereas the outer spiral bundle
region is yellow, due to approximate equivalence of the intensity of the red and green immunofluorescence in this region (see (E)). We attribute
double labeling (type II SGNs) versus single (b-tubulin) labeling (type I SGNs) from analysis of individual channels. Panels (A,C-E,G,H) are from
cryosectioned tissue; (B,F) are whole-mount preparations. Scale bars: 50 μm (A,B,E,F); 25 μm (C,D,G,H).
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this significant loss of type II SGNs occurred between
P1 and P7, where their density dropped from 121 ± 21
neurons/100 μm
3 to 15 ± 3 neurons/100 μm
3 (Holm-
Sidak test, P <0 . 0 5 ;8 8 %l o s s ) .N of u r t h e rr e d u c t i o n
was observed at P21, when type II SGN density was 15
±4n e u r o n s / 1 0 0μm
3. Thus, the type II SGN popula-
tion reduces from approximately 26% of all SGNs at
P1 to approximately 5% at P7. There was no marked
tonotopic effect on neuron density when the density of
type I and type II SGNs in each ganglion region was
plotted with respect to the distance from the apex
(Figure 3B and Figure 3C, respectively). These plots
confirm that type I SGNs show very little change in
n e u r o nd e n s i t yp o s t n a t a l l y( F i g u r e3 B ) ,b u tt h ef i v e -
fold reduction in the number of type II SGNs noted
Figure 2 Peripherin immunolabelled type II spiral ganglion neurons (SGNs) are absent at the apex of the cochlea and between P1 and
P7 their number reduces in the middle and basal regions. (A-I) Single plane confocal images of b-tubulin (green) and peripherin (red)
double immunolabeling of SGNs in the most apical region (apex) (A,D,G), and in the middle (B,E,H) and basal (C,F,I) turns in sectioned cochleae
from P1 (A-C), P7 (D-E) and P21 (G-I) mice. Marked areas are shown in insets and detail b-tubulin and peripherin immunolabeling of SGNs. b-
Tubulin and peripherin double immunolabeled type II SGNs are absent from the apex of P1 (A), P7 (D) and P21 (G) mouse cochleae. Many of
these double-immunolabeled type II SGNs are present in the middle and basal turns in P1 cochlea (B,C); however, this number is reduced in P7
(E,F) and P21 (H,I) cochleae. The level of b-tubulin expression in the type II SGN soma appears reduced in P7 and P21 cochleae, resulting in
relatively stronger red signal (peripherin channel). Scale bars: 50 μm.
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turns of the cochlea (excluding the very apex, where
there are no type II SGNs even at P1) (Figure 3C).
Spiral ganglion survival in vitro
Apoptosis is often controlled by the supply of trophic
support to afferent fibers by target tissue following
synaptogenesis [35]. To examine how peripheral trophic
support from the hair cells of the organ of Corti might
maintain type I and type II SGNs during the first post-
natal week of development, we investigated the survival
of these SGN sub-types in organotypic and explant cul-
tures where the organ of Corti was intact, or removed,
respectively. Subsequently the trophic effect of exogen-
ous BDNF on SGN subtypes in explant cultures was
examined. We first examined b-tubulin and peripherin
immunoreactivity in SGNs and their peripheral neurites
to confirm that peripherin expression remained specific
to mouse type II SGNs following 48 hours of culture
(Figure 4). Organotypic cultures of P7 cochleae - where,
in vivo, type I fibers innervate the IHC and type II fibers
innervate just the OHC - showed that the associated dif-
ferential immunolabeling was retained. Thus, in P7
organotypic tissue culture preparations, the IHC inner-
vation (ISP region) exhibited only b-tubulin immunola-
beling - consistent with type I SGN fibers (Figure 4A,B)
- whereas double immunolabeling for peripherin and b-
tubulin (of type II fibers) was similarly constrained to
the region of OHC innervation (the outer spiral bundle)
(Figure 4B,C).
Organotypic culture of P1 mouse cochlear tissue gave
rise to re-organization of the outer spiral bundle fibers,
as there was dense type II fiber labeling (b-tubulin and
peripherin) near the first row of OHCs (Figure 4D). The
ISP was composed of fibers that expressed either b-
tubulin only, or both peripherin and b-tubulin (Figure
4D). b-Tubulin and peripherin double-immunolabeled
fibers in the ISP (Figure 4D) appeared more prominent
than what we observed in in vivo P1 organ of Corti (Fig-
ure 1B) and b-tubulin-only-expressing type I fibers in
the ISP were diminished in density (Figure 4E) relative
to what we observed in vivo (Figure 1). This likely
reflected the significant loss of type I SGNs following
organotypic culture (Figure 5).
To investigate the pro-survival effect of the organ of
Corti on type I and type II SGNs, we assessed the in
vivo density of these neuronal sub-types in whole
mounts of the mid-apex-mid-turn region of cochleae
from P1 (Figure 5A) and P7 (Figure 5E) mice. These
densities were compared to those determined for the
spiral ganglion following 48 hour culture in control
media with the organ of Corti intact (organotypic, Fig-
ure 5B,F), or removed (explant - control, Figure 5C,G).
Figure 3 Quantitative analysis of type I and type II spiral
ganglion neuron (SGN) densities in P1, P7 and P21 mouse
cochlea shows selective loss of type II SGNs in the first
postnatal week in vivo. (A) Density of all SGNs, type I SGNs and
type II SGNs calculated from cell counts taken from mid-modiolar
cross-sections from P1 (black), P7 (grey) and P21 (white) mouse
cochlea. Mean density ± standard error of the mean; ANOVA, post
hoc Holm-Sidak test, **P < 0.01, ***P < 0.001. (B,C) The density of
type I (B) and type II (C) SGNs within different regions of the spiral
ganglion in mid-modiolar cross-sections are plotted against the
distance of the ganglia from the apex of the cochlea.
Barclay et al. Neural Development 2011, 6:33
http://www.neuraldevelopment.com/content/6/1/33
Page 5 of 14The effect of BDNF supplement in the culture media on
type I and type II SGN survival was also investigated in
SGN explants (explant plus BDNF, Figure 5D,H).
We validated our methods for calculating neuron den-
sity by comparing the in vivo d e n s i t yo ft y p eIa n dt y p e
II SGNs in the mid-apex-mid-turn region across two
different fresh-fixed tissue preparations; mid-modiolar
cross-sections (P1, n = 4; P7, n = 5) and whole mount
tissue (P1, n = 5; P7, n = 6), where we found no signifi-
cant difference in neuron density for each SGN sub-type
(Figure 5I,J). Forty-eight hour culture of type I SGNs
from P1 cochleae with the organ of Corti intact (orga-
notypic, n = 4) or removed (explant, n = 7) yielded sig-
nificant decreases in neuron density when compared to
in vivo densities calculated from whole mount tissue
( F i g u r e5 I ;w h o l em o u n tt i s s u e=5 0 6±3 6n e u r o n s / 1 0 0
μm
3; organotypic = 87 ± 22 neurons/100 μm
3; explant =
9±1n e u r o n s / 1 0 0μm
3;A N O V A ,P < 0.001). This loss
of neurons arose in both organotypic and explant cul-
tures (P <0 . 0 5 ,post hoc Holm Sidak test). The applica-
tion of BDNF to SGN explants (n = 7) improved
survival of cultured type I SGNs to 49 ± 9 neurons/100
μm
3 when compared to the control explants (Figure 5I;
unpaired t-test, P < 0.001). In contrast, at P1, while type
II SGNs also showed a significant effect of culture on
neuron density (Figure 5I; whole mount tissue = 103 ±
6n e u r o n s / 1 0 0μm
3;o r g a n o t y p i c=1 3 8±3 4n e u r o n s /
100 μm
3; explant = 7 ± 2 neurons/100 μm
3;A N O V A ,P
< 0.001), this loss of neuron viability only occurred in
the explant condition (P < 0.05, post hoc Holm Sidak
test). Thus, retention of the organ of Corti in the orga-
notypic culture preparations provided sufficient support
for complete survival of the type II SGN population.
The loss of type II SGNs in the explant preparation was
rescued by BDNF (Figure 5I; density was increased to
50 ± 8 neurons/100 μm
3; unpaired t-test, P <0 . 0 0 1 ) ,o r
about 50% survival, a considerably higher proportion
than the BDNF-mediated rescue of type I SGNs in
explants (Figure 5K).
Similar patterns of survival were observed in whole
mount (n = 4), organotypic (n = 7) and explant (n = 5)
tissue from P7 mice (Figure 5J). Type I SGNs again
showed a significant reduction in neuron density with
culture (whole mount tissue = 329 ± 32 neurons/100
μm
3; organotypic = 143 ± 20 neurons/100 μm
3;e x p l a n t
=2 0±3n e u r o n s / 1 0 0μm
3;A N O V A ,p < 0.001) that
arose in both organotypic and explant cultures (P <
0.05, post hoc Holm Sidak tests). BDNF yielded a signifi-
cant improvement in type I SGN survival, where an
increase of neuron density to 51 ± 6 type I neurons/100
μm
3 was observed when compared to control explants
(Figure 5J; unpaired t-test, P < 0.01). Type II SGNs also
showed a significant effect of culture on neuron density
( F i g u r e5 J ;w h o l em o u n tt i s s u e=2 2±1n e u r o n s / 1 0 0
Figure 4 The expression pattern of b-tubulin and peripherin in
type I and type II spiral ganglion neurons is maintained in vitro.
Maximum intensity projections from confocal z-stacks show
immunofluorescence labeling for b-tubulin (green) and peripherin
(red) in the mid-apex-mid-turn region of P1 (D,E) and P7 (A-C) mouse
cochlea following 48 hour organotypic culture (SGNs and organ of
Corti intact). Rhodamine-phalloidin labeling (grey in (B-E)) confirmed
the survival of target hair cells. (A,B) Immunolabeling of organotypic
cultures of P7 tissue shows the inner spiral plexus (isp), formed by type
I fibers, contains b-tubulin protein only (detailed in (B)), whereas the
outer spiral bundles (osb) that arise from type II fibers express both b-
tubulin and peripherin (arrows in (B,C)). (C) Examination of peripherin
immunofluorescence alone confirms that this protein is expressed only
in fibers that cross the tunnel of Corti and innervate the outer hair cells
(ohc). (D,E) Confocal imaging of organotypic culture of P1 cochlear
tissue shows that singularly b-tubulin immunofluorescent fibers
beneath the inner hair cells (ihc) are reduced in density compared to
the in vivo situation (compare (D) with Figure 1B). A large portion of
these fibers co-immunolabel for peripherin (D,E). The outer spiral
bundle double immunolabels with b-tubulin and peripherin (D,E).
Scale bars: 150 μm( A ) ;5 0μm( C - E ) .
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Page 6 of 14Figure 5 The organ of Corti (oC) maintains type II spiral ganglion neurons (SGNs), but not type I SGNs in organotypic culture and
brain-derived neurotrophic factor (BDNF) rescues a greater proportion of type II SGNs following explant culture without the oC. (A-
H) Single plane confocal images of b-tubulin (green) and peripherin (red) immunofluorescence in the mid-apex-mid-turn region of cochleae
from P1 (A-D) and P7 (E-H) mice enabled analysis of type I SGN (immunolabel for b-tubulin only) and type II SGN (immunolabel for b-tubulin
and peripherin) density. SGN density in the mid-apex-mid-turn region in vivo was determined in whole mount tissue (whole mount) (A,E).
Survival of SGN sub-types was subsequently established following 48 hour culture of cochlear tissue: retaining both SGNs and oC (organotypic)
(B,F); just the spiral ganglion, following removal of the oC (explant - control) (C,G) and this spiral ganglion explant cultured with 100 ng/ml BDNF
(explant + BDNF) (D,H). Inset shows marked area in corresponding panel at higher magnification and shows detail of type I and type II SGNs. (I,
J) Neuron densities for type I (green) and type II (red) SGNs from P1 (I) and P7 (J) mice are plotted for each condition shown in panels (A-H). x-
sect, mid-apex-mid-turn ganglion in mid-modiolar cross-sections; wm, whole mount; orgtyp, organotypic; expl BDNF, explant + BDNF; expl contr,
explant - control. Mean density and standard error of the mean; one-way ANOVA with post hoc Holm Sidak tests compare SGN survival in the
wm, orgtyp and expl contr; unpaired t-tests compare expl contr and expl BDNF; *P < 0.05, ***P < 0.001. (K,L) Percentage survival of type I and
type II SGNs in orgtyp, expl BDNF and expl contr relative to mean in vivo whole mount densities are plotted for P1 (K) and P7 (L) mice. Mean
density and standard error of the mean; unpaired t-test, *P < 0.05, **P < 0.01, ***P < 0.001. Scale bars: 250 μm.
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3; organotypic = 26 ± 3 neurons/100 μm
3;e x p l a n t=
6±2n e u r o n s / 1 0 0μm
3;A N O V A ,P < 0.001). Again it
was the explant cultures that exhibited a significant loss
of neurons when compared to the in vivo neuron den-
sity (whole mount tissue; P <0 . 0 5 ,post hoc Holm Sidak
test) and culture of type II SGNs with the organ of
Corti intact resulted in no significant change in their
density, indicating complete protection from type II
SGN loss. Culture of P7 SGN explants (no organ of
Corti) with BDNF significantly improved type II SGN
survival when compared to P7 explant cultures in con-
trol growth media (Figure 5J; 11 ± 1 type II neurons/
100 μm
3;u n p a i r e dt-test, P < 0.05). As for experiments
with P1 tissue, these P7 experiments again showed that
proportionally more type II neurons were rescued by
BDNF than type I SGNs (Figure 5L). Further, the com-
plete survival of type II SGNs in the P1 and P7
organotypic cultures validated our in vitro neuronal den-
sity quantification.
Spiral ganglion neuron neuritogenesis in vitro
Neurite outgrowth from spiral ganglia explants cultured
in control growth media (P1, n = 7; P7, n = 11) was
compared with that in explants with BDNF-supplemen-
ted culture medium (P1, n = 7; P7, n = 10). Minimal
neurite outgrowth was observed when P1 and P7
explants were cultured in control media (Figure 6A and
Figure 6C, respectively); however, the addition of BDNF
led to extensive neurite outgrowth at both P1 and P7
(Figure 6B and Figure 6D, respectively). The numbers of
neurites extending from each explant were counted and
the mean values ± standard error of the mean across
explants showed that the culture of the P1 mouse
cochlea with BDNF yielded highly significant increases
Figure 6 Brain-derived neurotrophic factor (BDNF) promotes neuritogenesis of both type I and type II spiral ganglion neurons (SGNs)
in explants, but has a greater effect on type II SGNs. (A-D) Analysis of neurite outgrowth in mid-apical-mid-turn region explants from P1 (A,
B) and P7 (C,D) mouse cochlea following 48 hour culture in control culture media (A,C) or with 100 ng/ml BDNF added to the media (B,D).
Confocal immunofluorescence images show type I SGN neurites (b-tubulin (green) only) and type II SGN neurites (b-tubulin and peripherin
(red)). (E,F) BDNF stimulated an increased number of type I (green) and type II (red) neurites per explant (E) and significantly longer type II
neurites (F). The neurites extend from the explants in bundles and then separate into individual fibers. This gives the appearance of branching
towards the ends in the low magnification images. Data are represented as mean and standard error of the mean; unpaired t-test, *P < 0.05, **P
< 0.01, ***P < 0.001. Scale bars: 250 μm.
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ure 6E). Type I neurites increased from 1 ± 0 to 53 ± 5
neurites/explant (unpaired t-test, P < 0.001) and type II
neurites increased from 3 ± 1 to 88 ± 16 neurites/
explant. P7 explants showed a similar, although rela-
tively more modest, effect (Figure 6E); the number of
type I neurites increased from 49 ± 11 neurites/explant
to 92 ± 7 neurites/explant with the addition of BDNF to
the growth media (unpaired t-test, P < 0.01) and type II
neurites increased significantly from 8 ± 2 neurites/
explant to 17 ± 1 neurites/explant (unpaired t-test, P <
0.001). There were significantly more type I neurites
than type II neurites in both control (unpaired t-test, P
< 0.05) and BDNF-treated (unpaired t-test, P < 0.001)
explants from P7 cochleae, which reflects the reduction
in numbers of type II SGNs in the explants at this later
age.
To investigate the effect of BDNF on the length of
type I and type II neurites, mean neurite length for
these SGN sub-types was calculated for each explant
(Figure 6F). Comparison of the mean lengths of type I
and type II neurites grown in control growth media
were not significantly different, regardless of age. Type I
and type II SGN neurites from P1 mice had a mean
length of 320 ± 38 μm and 343 ± 38 μm, respectively,
and those from P7 mice had a mean length of 481 ± 48
μm and 510 ± 77 μm, respectively. Addition of BDNF to
the culture medium stimulated a significant increase in
type II neurite length to 569 ± 67 μmi nP 1e x p l a n t s
(unpaired t-test, P < 0.05) and to 752 ± 50 μmi nP 7
explants (unpaired t-test, P < 0.05). Type I neurites
showed no BDNF-mediated increase in length (354 ± 40
μm at P1 and 600 ± 74 μm at P7; P > 0.05).
Discussion
Neonatal mouse cochlea provide a unique opportunity
in which to distinguish type I and type II SGNs using
peripherin as a specific marker for type II SGNs. We
show that approximately 25% of neurons at birth are
peripherin-positive and therefore type II SGNs. The api-
cal-most half turn of the mouse cochlea did not contain
peripherin-immunolabeled type II SGNs, in agreement
with previous studies [36,3 7 ] .O u rr e s u l t sa l s oa g r e e
with the previous study by Huang et al. [8] that first
demonstrated the specificity of peripherin immunolabel-
ing in the mouse cochlear type II SGN from embryonic
day 18. As shown by Huang et al., the peripherin-posi-
tive (type II SGN) neurites, which project beyond the
floor of the tunnel of Corti to the OHCs, formed dis-
tinctly separate fascicles from the transient innervation
of the OHCs by the peripherin-negative type I SGNs in
the first postnatal week. This reflects a species differ-
ence, as in the neonatal rat model, peripherin expression
occurs in type I as well as type II SGNs [36,31]. We are
also confident that peripherin expression remained con-
fined to the type II SGNs following axotomy and cul-
ture, despite previous reports of in vitro peripherin re-
expression in type I SGNs from rat cochlea following
axotomy and culture of SGN explants [31] and in vivo
following degeneration of the organ of Corti in response
to neomycin treatment [38]. In particular, we did not
observe peripherin expression in fibers innervating IHCs
in our organotypic cultures from P7 cochleae, by which
age the IHC innervation is exclusively from type I SGNs
[7]. Additionally, the density of peripherin-expressing
type II SGNs in these cultures matched the in vivo state,
again suggesting that type I SGNs in our cultures did
not start to express peripherin. It is highly unlikely that
exactly sufficient numbers of type I SGN could start to
express peripherin, to balance putative loss of type II
SGN, so that the peripherin-expressing neuron popula-
tion remained unchanged. It is also highly unlikely that
such a process would exactly match different propor-
tional loss of type II SGNs at P1 versus P7. These find-
ings are corroborated by previous studies in neonatal
mouse cultures, where peripherin was never observed in
type I fibers innervating the IHCs in organotypic cul-
tures [39] and where, following electrophysiological
recording from 228 SGNs in explant cultures, only 9
neurons were unequivocally identified as type II SGNs
based on their peripherin expression [32]. The periph-
erin-expressing fibers that we observed in the ISP region
at P1 likely represent type II fiber arbors that were
noted following organotypic culture of postnatal mouse
cochlear tissue [40].
Selective loss of type II SGNs during the first postnatal
week of development
Our data indicate that most of the known loss of approxi-
mately 25% of SGNs in vivo that occurs during the first
postnatal week [13,14] is accounted for by loss of type II
SGNs, and there is no significant change in type I SGN
density. Previous qualitative observations indicated that
at least a portion of SGN loss was accounted for by type
II neurons, as identified by their peripherin expression
[8] or location in Rosenthal’s canal [41]. Furthermore,
quantification of SGN loss in the human cochlea during
early development suggested that the proportion of type
II neurons decreased from 25% during early embryogen-
esis to 12% in the infant cochlea, based on reduction of
the proportion of smaller sized SGNs that were more
likely to be type II SGNs [42].
Dependence of type I and type II SGNs on endogenous
trophic support
Neuronal loss occurs extensively in the developing ner-
vous system and is thought to provide a means of
matching the size of a neuronal population with that of
Barclay et al. Neural Development 2011, 6:33
http://www.neuraldevelopment.com/content/6/1/33
Page 9 of 14their postsynaptic targets through competition for limit-
ing amounts of trophic support supplied by target tissue
[3,43,44]. Studies in the cochlea have shown that neona-
tal SGNs rely on connectivity with their peripheral tar-
gets for survival in vitro [45], and recently Brn3c3.1 null
mutants, which develop immature hair cells that die by
apoptosis during the neonatal period [46,47], concomi-
tantly lost more than 50% of their SGNs, including the
type II SGN innervation to OHCs by P7 [48]. Our
results indicate that connectivity between SGNs and the
hair cells of the organ of Corti promotes the survival of
both type I and type II SGNs postnatally. However,
whereas trophic support supplied by the sensory epithe-
lium was sufficient to maintain the entire population of
type II SGNs, it did not support the majority of type I
SGNs. This significant reduction in type I SGN density
in vitro that we quantified may arise from differential
sensitivity to disruption of SGN connectivity with the
cochlear nucleus. A recent study showed that loss of
neurons in especially the ventral cochlear nucleus
(mediated by the conditional deletion of the Atoh1 gene
in this region) led to the loss of approximately 30% of
SGNs between P0 and P3 [49]. Although the identity of
the lost SGNs was not known, substantial losses
occurred in regions of the spiral ganglion that are pre-
ferentially populated by type I SGNs. Interestingly, this
loss of SGN coincides with the period of initiation of
BDNF and NT-3 expression in the cochlear nucleus of
gerbils and rats [50,51] and the down-regulation of
these neurotrophins in the organ of Corti [19,21,22],
suggesting a switch of survival support from the sensory
epithelium to the central target. Our data suggest that
only the type I SGNs may be dependent upon the
cochlear nucleus during this period. This difference in
trophic dependence would help to explain the preferen-
tial loss of type II SGNs that occurs in vivo during this
p e r i o d .W h i l et h et y p eIS G N sm a yb ea b l et os u r v i v ea
r e d u c t i o ni nn e u r o t r o p h i np r o d u c t i o ni nt h eo r g a no f
Corti by switching dependence to a cochlear nucleus
source, type II SGNs appear to be independent of their
central targets and thus to be more dependent upon the
declining peripheral neurotrophic support. Our finding
that exogenous BDNF support provided significantly
greater survival of type II SGNs than type I SGNs in
vitro in explants at P1 corroborates the idea that the
early postnatal downregulation of this neurotrophin in
hair cells may give rise to the loss of type II SGNs in
vivo [22].
Refinement of type I and type II SGN innervation of the
developing organ of Corti
In addition to changes in neuronal survival, the first
postnatal week is a period of significant remodeling of
SGN neurites within the organ of Corti. Type I SGN
neurites retract from the region of the OHCs and focus
o nas i n g l eI H C ,w h i l et y p eI IS G Nn e u r i t e sw i t h d r a w
from the IHC region and substantially lengthen their
projection along the OHC region [7-11]. The reduction
of projections could be mediated by either the loss of
neurons or remodeling of existing neurites. Our obser-
vation that only type II SGNs are lost from the neonatal
SGN in vivo provides clarification, as the withdrawal of
type I neurites from beneath the OHCs during this per-
iod cannot be the result of neuronal loss, but must
represent the retraction of collateral neurites. In con-
trast, the reduction in type II dendrite presence under-
neath the IHCs could represent the loss of type II
neurons, dendrite remodelin g ,o rb o t h .A st h et y p eI I
neurites increase their projections beneath the OHCs,
they have been reported to retract collateral branches
extending toward the IHCs [8,52]. The specific marker
of type II SGNs - the type III intermediate filament per-
ipherin - may itself also bias this differential neurite out-
growth [28]. It is also possible that some type II neurons
originally projecting to the IHCs are lost. Our data can-
not distinguish between these alternatives.
Whereas BDNF supported the survival of both type I
and type II SGNs, this neurotrophin exerted a signifi-
cant effect only on neurite outgrowth in type II SGNs.
This was particularly evident at P1, corresponding to
the time when type II fibers extend into the OHC
region [7,8]. The differential effect of BDNF on neurito-
genesis in the two SGN populations likely reflects the
interaction of downstream signaling pathways, as TrkB
receptors are expressed by both type I and type II fibers
[53]. The nature of these differences is not clear. How-
ever, ATP signaling through ionotropic P2X receptors,
assembled as heteromers of P2X2 and P2X3 subunits,
has been shown to inhibit BDNF-dependent neurite out-
growth from SGNs [54]. In vivo studies with transgenic
mice provide compelling evidence that a primary role of
BDNF is to support the type II neurons and OHC inner-
vation throughout the cochlea as BDNF and TrkB null
mice exhibit selective loss (8 to 10%) of SGNs (type II)
and their fibers beneath the OHCs [23,27,55]. These
studies, and the finding that substitution of NT-3
expression for BDNF under the BDNF promoter rescues
the BDNF-dependent type II SGN innervation of OHCs,
indicates that there is redundancy in TrkB and TrkC
receptor signaling in the (type II) SGNs that respond to
the spatiotemporal regulation of neurotrophins (intrinsi-
cally BDNF) [27]. This is consistent with rescue of type
II SGNs by exogenous BDNF in our explant model, but
does not exclude complementary support from NT-3.
NT-3 has been shown to provide additive support to
BDNF in promoting survival of cultured gerbil and mur-
ine type II SGNs, and is synergistic with BDNF for type
I SGN survival just after birth [39]. Broader expression
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the NT-3-dependent loss of SGNs in the NT-3 null
mouse [22], again consistent with redundancy in Trk
receptor signaling associated with the spatiotemporal
compartmentalization of secretion of the neurotrophins
by the hair cells and supporting cells. While the putative
action of NT-3 in support of type I and type II SGNs
was not examined in the present study, it is apparent
f r o mt h e s et r a n s g e n i cm o d e l s ,a n df r o mo u rin vitro
data, that BDNF signaling is central to the development
of the type II innervation of OHCs.
Conclusion
Here we provide a comprehensive description of
changes in cochlear type I and type II SGNs of mouse
cochlea in vivo and in vitro during the critical period for
consolidation of their innervation of IHCs and OHCs,
respectively, in the first postnatal week. Our data show
that the substantial neuronal loss that occurs during this
period is attributable to type II SGNs alone and may
also contribute to the loss of their neurites from beneath
the IHCs. BDNF expression in the hair cells likely con-
tributes a large portion of trophic support that is neces-
sary for maintenance of this (type II) SGN sub-
population and may promote the extension of the outer
spiral bundle fibers along the rows of OHCs just after
birth. Our model of distinguishing type I and type II
SGNs will allow further investigation of the differential
effect of neurotrophins and guidance molecules on these
SGN sub-populations. This new knowledge of the prop-
erties of the two populations of primary auditory neu-
rons in the cochlea will bolster research on treatments
for auditory neuropathy, including research on afferent
regeneration.
Materials and methods
Animals
All procedures in the study were approved by the Uni-
versity of Auckland Animal Ethics Committee or by the
University of New South Wales Animal Care and Ethics
Committee. Cochlear tissue was obtained from P1 to
P21 C57/BL6 mice. P1 to P7 animals were killed by
decapitation, and older animals were killed by intraperi-
toneal injection of sodium pentobarbitol (90 mg/kg;
Nembutal, Virbac Laboratories, East Tamaki, New
Zealand).
Fixed tissue preparation
The innervation of the cochlea in vivo was determined
at P1, P7 and P21 by transcardial perfusion of 4% par-
aformaldehyde in 0.1 M phosphate buffer following
flushing with normal saline containing nitroprusside
(0.9% NaCl; 0.5% Na2[Fe(CN)5NO], pH 7.4). Cochleae
were subsequently perfused via the oval window with
4% paraformaldehyde in 0.1 M phosphate buffer and
post-fixed at 4°C overnight. Decalcification in 8%
EDTA in 0.1 M phosphate buffer (pH 7.4) at room
temperature was carried out for two (P7 to 14 tissue)
or 3 days (P21 tissue). The apical-most half turn of the
cochlear tissue was discarded and whole mount pre-
parations constituted one full turn of the cochlea, from
the mid-apex to mid-turn region. Bony capsule, lateral
wall, Reissner’s membrane and the modiolus were
removed, leaving the intact spiral ganglion and organ
of Corti. For mid-modiolar cross-sections, fixed
cochleae were placed in 10% sucrose in 0.1 M phos-
phate-buffered saline (PBS) for 4 hours, 30% sucrose in
0 . 1MP B Sf o r2d a y sa n dt h e na1 : 1m i xo f3 0 %
sucrose and Tissue-Tek OCT (Miles, Diagnostics Divi-
sion, Elkhart, IN, USA) for 1 hour. They were subse-
quently mounted in OCT, snap frozen on dry ice and
cryosections were cut at 50 μmi n t o0 . 1MP B S .F l o a t -
ing sections and whole mount tissue were subsequently
processed for immunofluorescence.
Organotypic and explant cultures
The survival and neurite outgrowth from neonatal (P1
to P7) SGNs were compared with and without the
organ of Corti to provide trophic support, as ‘organoty-
pic’ (spiral ganglion with organ of Corti intact) and
‘explant’ (spiral ganglion only) cultures. The cochlear
o t i cc a p s u l ew a sr e m o v e da n dt h et i s s u eah a l ft u r n
back from the apex, lacking type II SGNs, was dis-
carded. The modiolus was cut a further full turn down
to provide a mid-apical to mid-turn region. For organo-
typic cultures, the intact spiral ganglion, spiral limbus
and organ of Corti were retained. For explant cultures,
the organ of Corti and spiral limbus were removed to
isolate the spiral ganglion. Spiral ganglion plus organ of
Corti organotypic or SGN-only explant tissues were
transferred onto glass coverslips that were pre-coated
with 50 μg/ml poly-D-lysine (BD Biosciences, San
Diego, CA, USA) overnight at 4°C. These were placed in
single wells of a 24-well plate, each of which contained
200 μl neuron maintenance medium (DMEM (Gibco,
Carlsbad, CA, USA), 10% fetal bovine serum (Gibco), 10
μl/ml N2 supplement (Invitrogen, Carlsbad, CA, USA),
25 mM Hepes (Sigma-Aldrich, St Louis, MO, USA), 300
units/ml penicillin (Sigma-Aldrich), 6 mg/ml glucose
(Sigma-Aldrich)). Medium was replaced after the first 24
hours. In explant experiments, half of the explants also
contained 100 ng/ml of the neurotrophin BDNF (Pro-
mokine, Heidelberg, Germany), which was added to the
cell culture medium just prior to plating. Explants were
cultured at 37°C in a humidified incubator with 5% CO2
for 48 hours. Tissue was then fixed for 20 minutes with
4% paraformaldehyde, washed with PBS and processed
for immunofluorescence.
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Whole mounts, cryosections and cultured tissue were
incubated in blocking/permeablizing solution (10% nor-
mal goat serum and 2.5% Triton X-100 in PBS) for 2 to
3 hours at room temperature and then overnight at
room temperature in primary antibody solution: b-tubu-
lin antisera (1:500 dilution) and peripherin antisera
(1:1,000 dilution) with 5% normal goat serum and 0.25%
Triton X-100 in 0.1 M PBS. The following day, sections
were washed in PBS, then incubated for 2 hours at
room temperature in secondary antibody solution
(Alexa-488 conjugated goat anti-mouse IgG (1:500);
Alexa-594 conjugated goat anti-rabbit IgG (1:500);
Alexa-647 conjugated goat anti-rabbit (1:200); all from
Invitrogen) with 5% normal goat serum and 0.25% Tri-
ton X-100 in 0.1 M PBS. Cochlear tissue was washed
with PBS and in some experiments hair cells were
stained with 1:150 rhodamine-phalloidin (Invitrogen) in
PBS for 15 minutes at room temperature. Following
further washing with PBS, tissue was mounted on glass
slides in Vectastain (Vector Laboratories, Burlingane,
CA, USA) and stored at 4°C.
Background data on primary antibodies
A mouse monoclonal antibody against class III b-tubulin
(TUJ1 clone, Covance, Emeryville, CA, USA) was used
to label all SGNs and the expression we observed
reflected that previously described for rodent cochlear
tissue in vivo and in vitro [29,31]. Peripherin polyclonal
rabbit antiserum (PII/SE411; a gift from Dr Annie
Wolff, Division de Biochimie, Universite Pierre et Marie
Curie, Paris, France) was used to distinguish the type II
SGNs. This antibody specifically targets a peptide corre-
sponding to residues 432 to 461 of rat peripherin and
our immunolabeling of in vivo peripherin expression by
the type II SGNs matched that described by Huang et
al. [8], where the same peripherin antiserum was used.
Our peripherin immunoreactivity was also equivalent to
that previously described in cultured mouse cochlear tis-
sue [39]. We have also previously validated the specifi-
city of the peripherin antibody using peripherin null
mice [56].
Image acquisition and quantitative analysis
Images were acquired by confocal microscopy (Olympus
FV1000, Japan and Zeiss LSM710, Germany), saved as
TIFF files and processed using Adobe Photoshop CS2
(Adobe Systems, San Jose, CA, USA) and Image J (NIH,
USA) software. Levels were adjusted to remove back-
ground fluorescence, whilst ensuring that no neurite
detail was lost. Image J was used for all quantitative
analysis.
In vivo type I and type II SGN density was quantified
from mid-modiolar cross-sections of cochleae from P1,
P7 and P21 mice. The apex, apical, middle and basal
turn spiral ganglia in 50 μm cross-sections were imaged
using confocal microscopy with 5 μm between each
optical section. The volume of each ganglion was calcu-
lated by measuring the area of the spiral ganglion in
each optical section, converting this to a volume by
multiplying by 5 μma n ds u m m i n ga l lo ft h ev o l u m e s
within an image stack. b-Tubulin and peripherin pro-
vided good perinuclear immunolabeling of neurons and
thus permitted distinction of the nuclei in each cell.
Cells were counted in an optical section where the area
of the nucleus was greatest relative to the soma. For
example, analysis of nucleus area:soma area in consecu-
tive optical sections revealed that 5 μm z steps were suf-
ficient to ensure that in all cases the large round
nucleus (mean relative nucleus area at maximum size =
51%) could only appear in a single image; sections above
or below that showed only cytoplasm, or a small nucleus
that made up less than 34% of the cell area (n = 50);
thus, we were confident we were not counting a cell
more than once. Neuron counts from each optical sec-
tion were summed for each image stack to give a neu-
ron count for each ganglion. Neuron density (per 100
μm
3) was subsequently calculated. Our volumetric
approach encompassed variation in SGN somata size
and increases in the size of the spiral ganglion with
location and age, previously observed in the gerbil
cochlea between P0 and P21 [14]. The mean neuron
densities of all SGNs, and separately type I SGNs and
type II SGNs, were determined for each cochlea and
mean neuron density for each age was subsequently cal-
culated. Neuron densities in whole mounts (the in vivo
state) and following organotypic and explant culture of
the P1 and P7 cochleae were determined in the same
manner.
To investigate neurite outgrowth from control and
BDNF-treated P1 and P7 explants, single plane, confocal
images of explants were captured using a 5× or 10×
objective. NeuronJ (an ImageJ plugin) was used to trace
and measure neurite lengths. SigmaPlot 11 (Systat Soft-
ware Inc., Chicago, IL, USA) was used for all graphing
and statistical analyses. The normal distribution of data
was verified and statistical comparisons were made
using one-way ANOVA’sw i t hpost hoc Holm-Sidak
tests and Students two-tailed, unpaired t-tests.
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